LETROZOLE, RIBOCICLIB, GOSERELIN ACETATE, LEE011, TAMOXIFEN
CLEE011A2412B
Approved small_molecule active
Quick answer
LETROZOLE, RIBOCICLIB, GOSERELIN ACETATE, LEE011, TAMOXIFEN for HR+, HER2- advanced or metastatic breast cancer is a Approved program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- HR+, HER2- advanced or metastatic breast cancer
- Phase
- Approved
- Modality
- small_molecule
- Status
- active